NYSE:PBH

Prestige Consumer Healthcare Competitors

$45.22

+0.19 (+0.42 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$44.88

Now: $45.22▼

$45.73

50-Day Range

$41.71

MA: $44.31▼

$47.63

52-Week Range

$32.19

Now: $45.22▼

$47.98

Volume242,883 shs

Average Volume566,004 shs

Market Capitalization$2.25 billion

P/E Ratio14.04

Dividend YieldN/A

Beta0.76

Prestige Consumer Healthcare (NYSE:PBH) Vs. BBIO, MRTX, RARE, ARWR, GWPH, and ASND

Should you be buying PBH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Prestige Consumer Healthcare, including BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), and Ascendis Pharma A/S (ASND).

Prestige Consumer Healthcare vs. BridgeBio Pharma Stock

Prestige Consumer Healthcare (NYSE:PBH) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap consumer discretionary companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Prestige Consumer Healthcare and BridgeBio Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	17.03%	13.76%	4.80%
BridgeBio Pharma	N/A	-109.88%	-48.54%

Valuation & Earnings

This table compares Prestige Consumer Healthcare and BridgeBio Pharma's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$963.01 million	2.34	$142.28 million	$2.96	15.28
BridgeBio Pharma	$40.56 million	202.43	$-260,590,000.00	($2.48)	-22.23

Prestige Consumer Healthcare has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.5% of BridgeBio Pharma shares are held by institutional investors. 1.2% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Prestige Consumer Healthcare has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Prestige Consumer Healthcare and BridgeBio Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	0	3	3	0	2.50
BridgeBio Pharma	0	1	9	0	2.90

Prestige Consumer Healthcare presently has a consensus target price of $87.60, suggesting a potential upside of 93.72%. BridgeBio Pharma has a consensus target price of $72.8889, suggesting a potential upside of 32.24%. Given Prestige Consumer Healthcare's higher probable upside, equities analysts clearly believe Prestige Consumer Healthcare is more favorable than BridgeBio Pharma.

Summary

Prestige Consumer Healthcare beats BridgeBio Pharma on 8 of the 14 factors compared between the two stocks.

Prestige Consumer Healthcare vs. Mirati Therapeutics Stock

Prestige Consumer Healthcare (NYSE:PBH) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap consumer discretionary companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Institutional and Insider Ownership

94.9% of Mirati Therapeutics shares are held by institutional investors. 1.2% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 4.1% of Mirati Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for Prestige Consumer Healthcare and Mirati Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	0	3	3	0	2.50
Mirati Therapeutics	1	5	10	0	2.56

Prestige Consumer Healthcare presently has a consensus target price of $87.60, suggesting a potential upside of 93.72%. Mirati Therapeutics has a consensus target price of $218.5714, suggesting a potential upside of 38.17%. Given Prestige Consumer Healthcare's higher probable upside, equities analysts clearly believe Prestige Consumer Healthcare is more favorable than Mirati Therapeutics.

Valuation & Earnings

This table compares Prestige Consumer Healthcare and Mirati Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$963.01 million	2.34	$142.28 million	$2.96	15.28
Mirati Therapeutics	$3.34 million	2,398.14	$-213,260,000.00	($5.69)	-27.80

Prestige Consumer Healthcare has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Prestige Consumer Healthcare has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.

Profitability

This table compares Prestige Consumer Healthcare and Mirati Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	17.03%	13.76%	4.80%
Mirati Therapeutics	N/A	-60.01%	-54.21%

Summary

Prestige Consumer Healthcare beats Mirati Therapeutics on 8 of the 14 factors compared between the two stocks.

Prestige Consumer Healthcare vs. Ultragenyx Pharmaceutical Stock

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Ultragenyx Pharmaceutical and Prestige Consumer Healthcare, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	0	6	8	0	2.57
Prestige Consumer Healthcare	0	3	3	0	2.50

Ultragenyx Pharmaceutical presently has a consensus target price of $131.20, suggesting a potential upside of 20.68%. Prestige Consumer Healthcare has a consensus target price of $87.60, suggesting a potential upside of 93.72%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Ultragenyx Pharmaceutical.

Valuation and Earnings

This table compares Ultragenyx Pharmaceutical and Prestige Consumer Healthcare's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$103.71 million	70.18	$-402,730,000.00	($7.36)	-14.77
Prestige Consumer Healthcare	$963.01 million	2.34	$142.28 million	$2.96	15.28

Prestige Consumer Healthcare has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ultragenyx Pharmaceutical has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Profitability

This table compares Ultragenyx Pharmaceutical and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-119.19%	-50.69%	-26.87%
Prestige Consumer Healthcare	17.03%	13.76%	4.80%

Summary

Prestige Consumer Healthcare beats Ultragenyx Pharmaceutical on 8 of the 12 factors compared between the two stocks.

Prestige Consumer Healthcare vs. Arrowhead Pharmaceuticals Stock

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Arrowhead Pharmaceuticals and Prestige Consumer Healthcare, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	0	2	10	0	2.83
Prestige Consumer Healthcare	0	3	3	0	2.50

Arrowhead Pharmaceuticals presently has a consensus target price of $85.3077, suggesting a potential upside of 26.10%. Prestige Consumer Healthcare has a consensus target price of $87.60, suggesting a potential upside of 93.72%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Arrowhead Pharmaceuticals.

Valuation and Earnings

This table compares Arrowhead Pharmaceuticals and Prestige Consumer Healthcare's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$87.99 million	79.80	$-84,550,000.00	($0.84)	-80.54
Prestige Consumer Healthcare	$963.01 million	2.34	$142.28 million	$2.96	15.28

Prestige Consumer Healthcare has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Profitability

This table compares Arrowhead Pharmaceuticals and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-96.09%	-17.37%	-15.19%
Prestige Consumer Healthcare	17.03%	13.76%	4.80%

Summary

Prestige Consumer Healthcare beats Arrowhead Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Prestige Consumer Healthcare vs. GW Pharmaceuticals Stock

GW Pharmaceuticals (NASDAQ:GWPH) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

81.0% of GW Pharmaceuticals shares are held by institutional investors. 3.1% of GW Pharmaceuticals shares are held by insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for GW Pharmaceuticals and Prestige Consumer Healthcare, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GW Pharmaceuticals	0	10	4	0	2.29
Prestige Consumer Healthcare	0	3	3	0	2.50

GW Pharmaceuticals presently has a consensus target price of $204.0909, suggesting a potential downside of 6.77%. Prestige Consumer Healthcare has a consensus target price of $87.60, suggesting a potential upside of 93.72%. Given Prestige Consumer Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than GW Pharmaceuticals.

Valuation and Earnings

This table compares GW Pharmaceuticals and Prestige Consumer Healthcare's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GW Pharmaceuticals	$311.33 million	22.04	$-9,020,000.00	($0.24)	-912.08
Prestige Consumer Healthcare	$963.01 million	2.34	$142.28 million	$2.96	15.28

Prestige Consumer Healthcare has higher revenue and earnings than GW Pharmaceuticals. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

GW Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Profitability

This table compares GW Pharmaceuticals and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GW Pharmaceuticals	-11.05%	-7.46%	-6.13%
Prestige Consumer Healthcare	17.03%	13.76%	4.80%

Summary

Prestige Consumer Healthcare beats GW Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Prestige Consumer Healthcare vs. Ascendis Pharma A/S Stock

Ascendis Pharma A/S (NASDAQ:ASND) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Profitability

This table compares Ascendis Pharma A/S and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-4,042.79%	-55.72%	-49.42%
Prestige Consumer Healthcare	17.03%	13.76%	4.80%

Volatility and Risk

Ascendis Pharma A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Valuation and Earnings

This table compares Ascendis Pharma A/S and Prestige Consumer Healthcare's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$14.98 million	437.57	$-244,180,000.00	($5.25)	-23.23
Prestige Consumer Healthcare	$963.01 million	2.34	$142.28 million	$2.96	15.28

Prestige Consumer Healthcare has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Ascendis Pharma A/S and Prestige Consumer Healthcare, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0	1	11	0	2.92
Prestige Consumer Healthcare	0	3	3	0	2.50

Ascendis Pharma A/S presently has a consensus target price of $187.6667, suggesting a potential upside of 53.89%. Prestige Consumer Healthcare has a consensus target price of $87.60, suggesting a potential upside of 93.72%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Ascendis Pharma A/S.

Summary

Prestige Consumer Healthcare beats Ascendis Pharma A/S on 8 of the 12 factors compared between the two stocks.